ATE453392T1 - Imidazolcarbonsäurealkylester-haltiges medikament zur behandlung neurodegenerativer erkrankungen - Google Patents
Imidazolcarbonsäurealkylester-haltiges medikament zur behandlung neurodegenerativer erkrankungenInfo
- Publication number
- ATE453392T1 ATE453392T1 AT07252120T AT07252120T ATE453392T1 AT E453392 T1 ATE453392 T1 AT E453392T1 AT 07252120 T AT07252120 T AT 07252120T AT 07252120 T AT07252120 T AT 07252120T AT E453392 T1 ATE453392 T1 AT E453392T1
- Authority
- AT
- Austria
- Prior art keywords
- mcg
- treatment
- administered
- imidazole
- neurodegenerative diseases
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- GYTMUNSNMBRSEW-UHFFFAOYSA-N hydrogen carbonate;1h-imidazol-1-ium Chemical compound OC(O)=O.C1=CNC=N1 GYTMUNSNMBRSEW-UHFFFAOYSA-N 0.000 title 1
- KYWMCFOWDYFYLV-UHFFFAOYSA-N 1h-imidazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=CN1 KYWMCFOWDYFYLV-UHFFFAOYSA-N 0.000 abstract 2
- 125000005907 alkyl ester group Chemical group 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- DVLGIQNHKLWSRU-UHFFFAOYSA-N methyl 1h-imidazole-5-carboxylate Chemical compound COC(=O)C1=CN=CN1 DVLGIQNHKLWSRU-UHFFFAOYSA-N 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000000065 osmolyte Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80803206P | 2006-05-23 | 2006-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE453392T1 true ATE453392T1 (de) | 2010-01-15 |
Family
ID=38469973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07252120T ATE453392T1 (de) | 2006-05-23 | 2007-05-23 | Imidazolcarbonsäurealkylester-haltiges medikament zur behandlung neurodegenerativer erkrankungen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7666893B2 (de) |
| EP (1) | EP1859800B1 (de) |
| AT (1) | ATE453392T1 (de) |
| AU (1) | AU2007202334A1 (de) |
| CA (1) | CA2589819C (de) |
| DE (1) | DE602007004018D1 (de) |
| NZ (1) | NZ555337A (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9737552B2 (en) | 2010-12-14 | 2017-08-22 | The Johns Hopkins University | Treatment of cognitive impairment in a subject with a neurological autoimmune disease |
| EP4338740A1 (de) | 2022-09-13 | 2024-03-20 | Johannes Gutenberg-Universität Mainz | Transdermales pflaster zur förderung oder beschleunigung der myelinisierung und/oder remyelinisierung |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4055573A (en) * | 1976-05-06 | 1977-10-25 | Smithkline Corporation | Electrochemical reduction of imidazolecarboxylic esters |
| US6426360B1 (en) * | 1994-07-28 | 2002-07-30 | G D Searle & Co. | 4,5-substituted imidazolyl compounds for the treatment of inflammation |
| US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US6277402B1 (en) * | 1998-06-26 | 2001-08-21 | Delack Elaine Alice | Method for treatment of multiple sclerosis and related disease states |
| EP1098885B9 (de) * | 1998-07-23 | 2005-05-18 | Fujisawa Pharmaceutical Co., Ltd. | Imidazolverbindungen und ihre verwendung als adenosindeaminase-inhibitoren |
| AUPP921299A0 (en) * | 1999-03-15 | 1999-04-15 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
-
2007
- 2007-05-23 DE DE602007004018T patent/DE602007004018D1/de active Active
- 2007-05-23 AT AT07252120T patent/ATE453392T1/de not_active IP Right Cessation
- 2007-05-23 NZ NZ555337A patent/NZ555337A/en not_active IP Right Cessation
- 2007-05-23 US US11/805,624 patent/US7666893B2/en not_active Expired - Fee Related
- 2007-05-23 EP EP07252120A patent/EP1859800B1/de not_active Not-in-force
- 2007-05-23 CA CA2589819A patent/CA2589819C/en not_active Expired - Fee Related
- 2007-05-23 AU AU2007202334A patent/AU2007202334A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE602007004018D1 (de) | 2010-02-11 |
| AU2007202334A1 (en) | 2007-12-13 |
| EP1859800A1 (de) | 2007-11-28 |
| US7666893B2 (en) | 2010-02-23 |
| CA2589819C (en) | 2015-07-07 |
| NZ555337A (en) | 2009-03-31 |
| CA2589819A1 (en) | 2007-11-23 |
| US20070276021A1 (en) | 2007-11-29 |
| EP1859800B1 (de) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Colzi et al. | Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease | |
| EP2746251A3 (de) | Positiv geladene, wasserlösliche Prodrugs von Acetaminophen und verwandte Verbindungen mit sehr schneller Hautpenetrationsrate | |
| EA201500553A1 (ru) | Многодневный пластырь для чрескожного введения ротиготина | |
| HRP20191029T1 (hr) | Derivati morfinana radi liječenja predoziranja lijekom | |
| WO2011098539A1 (en) | Treatment of loss of sense of touch with saxitoxin derivatives | |
| JP2017534613A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| US20250319074A1 (en) | Treatment and management of augmentation in restless legs syndrome | |
| US20140045801A1 (en) | Pramipexole transdermal delivery for severe headaches | |
| ATE353645T1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| US20080176913A1 (en) | Transdermal compositions of pramipexole having enhanced permeation properties | |
| US20150352040A1 (en) | Topical peripheral neuro-affective (tpna) therapy | |
| MY142431A (en) | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | |
| JP2016505050A5 (de) | ||
| ATE453392T1 (de) | Imidazolcarbonsäurealkylester-haltiges medikament zur behandlung neurodegenerativer erkrankungen | |
| SK286260B6 (sk) | Ošetrovanie migrény podávaním kyseliny alfa-lipoovej alebo jej derivátov | |
| JP2016539167A (ja) | ダントロレンの髄腔内投与による痙縮の治療 | |
| EP3134417A1 (de) | Kleinmolekülige analoga von e4orf1 | |
| CN116685316A (zh) | 用于治疗脂质相关失调的组合物和方法 | |
| CA2986941C (en) | New use of isoquinoline derivatives for diabetic wound healing | |
| JP6869893B2 (ja) | 前頭葉機能障害治療剤 | |
| US20160058752A1 (en) | Topical peripheral neuro-affective (tpna) therapy for neuropathic conditions | |
| RU2823100C2 (ru) | Анальгетическая субстанция эндогенной природы, фармацевтическая композиция на ее основе и способы их применения | |
| RU2019120527A (ru) | Замещенное производное бензимидазола в качестве модулятора активности tnf | |
| CN117503779A (zh) | 一种基于原人参二醇药剂的制备方法及其应用 | |
| EE200100193A (et) | 3-(1H-imidasool-4-ülmetüül)-indaan-5-ol'i kasutamine intraspinaalselt, teekasiseselt või epiduraalselt manustatava ravimi tootmises |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |